目的：探讨贝伐单抗联合培美曲塞及顺铂治疗晚期非小细胞肺癌的疗效。方法将46例非小细胞肺癌患者随机分为给予贝伐单抗联合培美曲塞＋顺铂化疗的观察组和给予培美曲塞＋顺铂化疗的对照组，观察化疗后肿瘤缓解情况、分期情况以及肿瘤内分泌指标。结果化疗后，观察组缓解有效率（56．52％）、疾病控制率（78．26％）、肿瘤分期均明显优于对照组（P＜0．05）；观察组VEGFA、VEGFB以及VEGFC的mRNA水平（62．4±8．4、44．8±6．2、57．2±6．2）pg/ml、蛋白水平（82．3±11．2、77．9±9．5、52．3±7．3）pg/ml均明显低于对照组（P＜0．05）。结论贝伐单抗联合培美曲塞＋顺铂化疗有助于提高缓解率和降低肿瘤分期，并降低血管内皮生长因子含量，具有积极的临床价值。%Objective To study the effect of bevacizumab combined with pemetrexed +cisplatin for advanced non-small cell lung cancer .Methods 46 non-small cell lung cancer patients were randomly divided into the observation group who received bevacizumab combined with pemetrexed +cisplatin,and the control group treated with pemetrexed +cisplatin.Tumor remis-sion,clinical stage and tumor endocrine index were observed .Results After chemotherapy,remission rate(56.52%),disease control rate(78.26%),tumor stage in the observation group were significantly better than those of the control group (P<0.05);mRNA and protein level of VEGFA ,VEGFB and VEGFC in the observation group were (62.4 ±8.4、44.8 ±6.2 and 57.2 ±6.2) pg/ml and(82.3 ±11.2、77.9 ±9.5、52.3 ±7.3)pg/ml,which were significantly lower than those of the control group (P<0.05).Conclusion Bevacizumab combined with pemetrexed +cisplatin can improve the remission rate ,degrade tumor stage, and decrease vascular endothelial growth factor level .It has positive clinical value .
展开▼
